

Our Ref: 296/2020
November 2020

Re: Your request made under the Freedom of Information Act 2000

I am analysing the usage of anti-VEGF treatments for eye conditions. I would greatly appreciate if you could answer two questions:

- 1) Within your trust how many patients over the last 12 months (November 2019 to October 2020 or latest available) have received the following anti-VEGF treatments:
 - Aflibercept **1,153**
 - Bevacizumab **39**
 - Brolucizumab **0**
 - Dexamethasone **26**
 - Fluocinolone acetonide **3**
 - Ranibizumab **132**

- 2) For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.
 - Aflibercept **337**
 - Bevacizumab **24**
 - Brolucizumab **0**
 - Dexamethasone **20**
 - Fluocinolone acetonide **3**
 - Ranibizumab **25**